Chiasma secures new funding to support Phase III oral octreotide programme
This article was originally published in Scrip
Chiasma has closed $38.5 million in equity financing to fund the completion of Phase III development for Octreolin, the private company's proprietary oral form of the peptide octreotide for the treatment of acromegaly and neuroendocrine tumours.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.